Tscan Therapeutics, INC 8-K filings

NASDAQ

6 Mar 2024

TCRX

8-K: TScan Therapeutics Reports Positive Clinical Trial Data and Financial Results for 2023

TScan Therapeutics announced positive results from its Phase 1 clinical trials for hematologic malignancies, progress in its solid tumor program, and its financial results for the fourth quarter and full year 2023.

NASDAQ

29 Jan 2024

TCRX

Tscan Therapeutics, INC

8-K: TScan Therapeutics Appoints Jason A. Amello as Chief Financial Officer

TScan Therapeutics has appointed Jason A. Amello as its new Chief Financial Officer, effective January 29, 2024.